Form 4: BioAge Labs CMO Sells Shares After Option Exercise

BioAge Labs' Chief Medical Officer, Paul D. Rubin, exercised stock options and subsequently sold 68,897 shares of common stock for approximately $701,800.

Summary

• Paul D. Rubin, Chief Medical Officer of BioAge Labs, Inc. (BIOA), reported a transaction involving the exercise of stock options and the sale of common stock.
• On December 4, 2025, Mr. Rubin acquired 68,897 shares of BioAge Labs Common Stock by exercising stock options at a price of $4.11 per share, totaling $283,176.67.
• Concurrently, Mr. Rubin disposed of all 68,897 shares of Common Stock at a weighted average price of $10.1878 per share, generating approximately $701,800.00 in proceeds.
• The shares were sold in multiple transactions within a price range of $10.00 to $10.96 per share.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Rubin on November 5, 2024.
• Following these transactions, Mr. Rubin's direct beneficial ownership of Common Stock is 0 shares, while he retains 21,736 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, this transaction is a routine exercise-and-sell under a pre-arranged 10b5-1 plan, common for executive compensation and liquidity. The significant profit indicates the options were in-the-money.

Positives

• The Chief Medical Officer exercised stock options, indicating a belief in the value of the underlying shares at the time of vesting and exercise.
• The sale price of $10.1878 per share is significantly higher than the exercise price of $4.11 per share, resulting in a substantial gain for the insider.

Negatives

• The Chief Medical Officer sold all shares acquired from the option exercise, which could be interpreted by some investors as a lack of long-term conviction, although it is a common practice for compensation and liquidity.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This transaction is an individual insider trading activity and does not directly reflect broader industry trends. It is a common practice for executives to exercise vested stock options and sell the resulting shares for liquidity or diversification, often under a pre-arranged Rule 10b5-1 plan.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider sale as a signal, though the pre-arranged nature under a 10b5-1 plan mitigates concerns about opportunistic selling. The profit realized by the CMO reflects the increase in share value since the options were granted.
• Employees: No direct impact mentioned.

Key Dates

Keywords

BioAge Labs, BIOA, Insider Trading, Form 4, Stock Option Exercise, Common Stock Sale, Paul D. Rubin, Chief Medical Officer, Rule 10b5-1 Plan